LIFE SCIENCES AND BIOMANUFACTURING STRATEGY
Progress Report 2023-2024
Signage being installed atop AbCellera’s new Vancouver office at 150 West 4th Avenue, as the BC-based company expands its local workforce and brings new treatments into clinical development. Credit: AbCellera
Joint letter from Minister Bailey and Minister Dix

When our government began developing British Columbia’s first Life Sciences and Biomanufacturing Strategy, the world was still grappling with the COVID-19 pandemic. That public health emergency demonstrated the strength of the life sciences and biomanufacturing sector in B.C. It also presented opportunities to help solve more health-care challenges for people, and for the sector to expand at home and globally.

Since then, our government has been delivering on our vision to position British Columbia as a global hub for life sciences and biomanufacturing, and as a leading centre for commercial-scale biopharmaceutical and medical manufacturing. We are working with our partners on major projects like building and operationalizing the Clinical Support and Research Centre at St. Paul’s Hospital campus, and establishing B.C.’s first non cancer Phase 1 clinical trial facility at Mount St Joseph’s Hospital. In Vancouver, we’re supporting significant expansions by AbCellera which will boost B.C.’s capacity for therapeutics discovery and increase access to clinical trials, and Aspect Biosystems which will advance bio-printed tissue therapeutics development here in British Columbia, including R&D, clinical trials and production capacity for innovative medicines to fight numerous diseases. And we’re making investments in new wet lab and biomanufacturing facilities in Vancouver and on Vancouver Island, which will provide opportunities for emerging, leading companies to move forward. These projects and many others will provide the critical space and infrastructure needed to create a healthy future for people. By improving health research and clinical trials capacity in the province we are insuring that B.C. clinicians remain world leaders in health research, improving B.C. residents access to world leading treatment and diagnostics and ensuring a strong foundation to the life sciences industry.

B.C.’s incredibly gifted, world-leading researchers and entrepreneurs are at the heart of our strategy, and they continue to make exciting progress in fourth-generation therapeutics, including cellular therapies and radiopharmaceuticals. This high calibre activity is attracting more talent and capital to our province, and creating a strong, vibrant ecosystem for innovation to thrive.

Because our rapidly accelerating sector needs more qualified talent, we are adding new seats at post-secondary institutions and funding a new internationally recognized training program at BCIT. Our government has also approved new training micro-credentials to help people add to existing skills and meet the needs of the sector.

B.C. is home to the fastest growing life sciences sector in Canada with over 2,000 companies employing close to 20,000 people in the province. With the support of all of our partners in government, industry, academia, the health-care sector and beyond, and with the incredible breadth of talent in B.C., we will continue building on the foundation we’ve created to make life better for people in B.C. and globally.

This report highlights many of the actions we’ve taken through our Life Sciences Strategy that align with our Industrial Blueprint to drive new investment, create new jobs, and seize new opportunities in growing clean energy and sustainable industries. By leveraging B.C.’s strengths to create good jobs and opportunities in every community and every sector, we are improving the quality of life for people, creating stronger patient outcomes and health-care delivery while strengthening the province’s diverse economy.
The B.C. Government has invested $737 million in the B.C. life sciences sector.

This investment has leveraged over $1.2 billion in federal and private funding.

**Improved access to talent:**
- Invested $2 million to deliver an internationally recognized biomanufacturing curriculum at the BC Institute of Technology (BCIT) in partnership with the Canadian Alliance for Skills and Training in Life Sciences (CASTL).
- Supported the development of new training micro-credentials in life sciences areas.
- Contributed to a study on the labour market needs of B.C.’s life sciences sector.
- Added “biological technologists and technicians” to the BC Provincial Nominee Program (BC PNP).
- Provided support for 10,000 paid Mitacs internships over five years.

**Supported innovative local companies:**
- Announced $12.5 million in funding for wet labs in Vancouver and on southern Vancouver Island.
- Delivered grants to increase productivity through the BC Manufacturing Jobs Fund.
- Participated in international trade missions to build industry connections.
- Provided support for entrepreneurs with B.C.’s Intellectual Property Strategy, the Trade Diversification Strategy, and Clean and Competitive: A Blueprint for B.C.’s Industrial Future.

At B.C.’s StarFish Medical, an optical engineer adjusts a Michelson interferometer next to a 1D OCT probe system. Credit: StarFish Medical.
Increased our biomanufacturing capacity for anchor companies:

- Announced $75 million for AbCellera to build a preclinical development facility
- Announced $23.75 million in funding for Aspect Biosystems to build a full-stack biomanufacturing facility
- Announced $32 million to expand TRIUMF’s laboratory and production capacity in support of cancer research and treatment using radiation therapy and rare isotopes

Expanded our clinical trials capacity:

- Invested $4.2 million to create B.C.’s first non-cancer Phase 1 clinical trials unit
- Endowed a new clinical pharmacology research chair at the University of British Columbia (UBC) with $2.4 million to focus on trials
- Developed a shared vision for clinical trials in B.C.
- Actively streamlining the approval process for health research

Leveraged and commercialized our research capacity:

- Invested $331.7 million towards the Clinical Support and Research Centre on the campus of the new St. Paul’s Hospital in downtown Vancouver, a transformative project for B.C.
- Invested more than $38 million for life sciences research infrastructure
- Announced $195 million in funding for Michael Smith Health Research BC and Genome BC and $20 million to Canada’s Michael Smith Genome Sciences Centre to support research projects and genome sequencing in collaborations with clinicians
The Strategy

In April 2023, the Province launched the B.C. Life Sciences and Biomanufacturing Strategy – a vision for the future that builds on our province’s strengths and maximizes opportunities in the global innovation economy.

The strategy identifies five pillars to support continued growth of the sector:

1. **Improving access to talent:** By increasing our talent pool through collaboration with industry, academia and other organizations, B.C. will ensure that current and future employees have the skills they need to grow.

2. **Growing innovative local companies:** With partners, B.C. will make it easier for life sciences companies to access the physical space, supports and funding they need to thrive.

3. **Increasing biomanufacturing capacity and attracting anchor companies:** By creating the right conditions, B.C. will attract and retain anchor companies and support home-grown success stories.

4. **Expanding our clinical trials capacity:** By expanding our capacity to conduct clinical trials, B.C. will maximize health, educational and economic benefits for British Columbians.

5. **Leveraging and commercializing research capacity:** By continuing to support life sciences and biomedical research translation into commercial products that improve health, B.C. will gain a competitive advantage worldwide.

As outlined in the pages that follow, the Province is collaborating with partners and stakeholders to strengthen these pillars and deliver on our vision: To position British Columbia as a global hub for life sciences and biomanufacturing, and as a leading centre for commercial-scale biopharmaceutical and medical manufacturing.

This progress report reflects the involvement and funding of many provincial government ministries in supporting the strategy’s goals.

“The strategy is unprecedented – the result of cross-ministry collaboration between the ministries of Health and Jobs, Economic Development and Innovation – and demonstrates understanding by government of the double benefit of the life sciences sector and commitment to grow it.”

*Wendy Hurlburt, president and CEO of Life Sciences BC; Ali Ardakani, founder and managing director, Novateur Ventures*
Economic Context

The life sciences sector stands out as one of the most innovative sectors in the global economy. Companies in B.C., alongside their global counterparts, experienced robust growth during and immediately following the pandemic. In fact, during that time, B.C. was Canada's fastest-growing life sciences sector.\(^1\) The sector benefited from a record $3.3 billion in private investment, fuelling a heightened focus on biotechnology and pharmaceuticals. Between 2018 and 2021 (the most recent year for which data was available), B.C. saw a remarkable:

- 26.5% increase in the number of life sciences businesses, compared to 2.7% for all sectors
- 23.2% increase in the number of employees, compared to 0.6% for all sectors
- 36.9% increase in wages and salaries, compared to 16.9% for all sectors
- 29.7% in GDP-growth for the life sciences sector, compared to 8.7% for all sectors
- 36.5% increase in service exports, compared to a 7.9% decline for all sectors

Since the strategy was announced in April 2023, much has changed in the economic and geopolitical context. Investments have cooled as a result of higher interest rates, persistent inflation and geopolitical tensions. This is not unique to B.C. There's been a sharp decline in investments globally over the past two years, and life sciences companies are shifting their portfolio strategies with the hope of continuing on their previous growth trajectory.\(^2\)

B.C. has weathered this broader decline with considerable resilience, demonstrating the underlying strength of the sector. This is exemplified by noteworthy deals including Aspect Biosystem's partnership with Novo Nordisk, valued at up to $3.5 billion; Chinook Therapeutics' acquisition by Novartis for $4.7 billion; and the recent $27-million investment from Amgen to expand its research facility in Burnaby.

The pandemic underscored vulnerabilities in global supply chains. This prompted a strategic push from the Province to enhance local production that would both maximize value chain benefits for B.C. and support Canada's pandemic preparedness. Intense construction is now underway, with new facilities for AbCellera, Aspect Biosystems, adMare and TRIUMF bringing critical capacity to our province and reducing our vulnerability to future public health threats.

Despite these strides, there are still challenges in bringing innovative products to market and integrating them into existing health-care systems. Looking ahead, B.C.'s strategy will continue to foster and fortify the sector. This past year has shown the importance of partnerships and collaboration. The resilience of the sector in the face of a shifting investment landscape and economic and geopolitical uncertainty is a result of government, industry, academia and investors working together to make B.C. a global leader in life sciences and biomanufacturing.

---

\(^1\) All data taken from Life Sciences in British Columbia: Sector Profile, May 2023.  
\(^2\) Deloitte. 2023 Global Life Sciences Outlook.
Growing B.C.’s life sciences and biomanufacturing sector requires talented people with specialized skills and knowledge. The province needs research scientists and lab techs, AI experts and equipment operators, innovators in labs and leaders who can advance a company from a startup to a success story.

To create the talent B.C. needs, the Province has committed to:

- Building a biomanufacturing talent pipeline for industry
- Supporting traditional new-talent pipelines
- Developing a pool of new and experienced leaders

Helping individuals gain hands-on training

B.C. is investing in the future by providing access to specialized skills and hands-on training. In 2023, the Province announced a $2-million investment in the National Biomanufacturing Training Centre at BCIT. Through its partnership with CASTL, the training centre will deliver a globally recognized curriculum and industry-informed training in biopharmaceutical manufacturing. On-site industry training will begin in the fall of 2024, where trainees will gain hands-on experience in using pilot-scale bioprocessing equipment in clean room environments.
New micro-credential offerings

Micro-credentials are a flexible and accessible way for people to quickly obtain new skills through targeted short-duration training. The Ministry of Post-Secondary Education and Future Skills has funded the development of new micro-credentials at BCIT, UBC and the University of Victoria in animal cell culture, metabolomics, regulatory affairs and biomedical device development.

Meeting employers’ needs for highly trained employees

In April 2023, the Province announced its support for 10,000 new paid Mitacs internships over five years. These will be in priority sectors, including life sciences and biomanufacturing. Mitacs internships facilitate connections between students, post-secondary institutions, and industry and not-for-profit partners.

In 2023 the Province also announced an additional 3,000 tech-relevant student spaces in the post-secondary education system as part of the Stronger BC: Future Ready Action Plan. The expansion will enable more students to pursue credentials in programs related to the life sciences and biomanufacturing sector, such as those recently announced at UBC for biomedical engineering, microbiology and immunology, and pharmaceutical sciences.

Understanding labour market shortfalls

Industry employers reported that the skills gap is a significant barrier to long-term growth. That gap is widening fast – and is currently projected to increase ten-fold over the next three years. A Labour Market Intelligence Study published in February 2024 estimated that over 5,500 new positions will need to be filled by 2027. In collaboration with stakeholders, the Province is using these findings to inform policy decisions and guide continued investment in skills development to address this labour shortage.

Prioritizing in-demand occupations through the B.C. immigration program

B.C. uses its immigration program, the BC Provincial Nominee Program (BC PNP), as one way to address the skills gap. The BC PNP provides an immigration pathway for prospective immigrants who will contribute their expertise in high-demand areas in B.C.’s economy. In 2022, B.C. added new priority sectors, expanding the list of eligible occupations within the BC PNP. This will make it easier for those with sought-after skills in health-care occupations – including life science occupations such as biological technologists and technicians – to immigrate to, and work in, B.C.
Our Progress

Pillar 2: Growing innovative local companies

Investing in specialized wet labs

Starting in 2025, early-stage biotechs will be able to lease space from adMare BioInnovations in its new 30,000-square-foot facility in Vancouver’s False Creek area, a growing hub of life sciences companies. In April 2023, the Province announced $10 million in funding for the facility, which will be able to support over 20 early-stage ventures. adMare has already helped build 29 companies that have attracted more than $2.3 billion in capital.

In May 2023, the Province announced $2.5 million to Vancouver Island Life Sciences to create a dedicated biomanufacturing facility with lab space for up to six companies on southern Vancouver Island. This will provide the essential space for companies to advance their early-stage discoveries through the development process towards commercialization.

A research discovery in a lab can lead to a life-saving therapeutic or medical device. The successful transition from discovery to product depends on specialized labs that can safely handle chemicals, small-scale manufacturing facilities to test products and venture capital to support growth.

To create an environment where local companies can grow, B.C has committed to:

- Increasing available wet lab space and small-scale biomanufacturing facilities
- Improving access to capital
- Establishing intellectual property strategies
Accelerating productivity

Manufacturers can now get targeted funding through the BC Manufacturing Jobs Fund to plan and develop capital projects to help modernize their facilities, innovate and be more competitive. Announced in 2023 under the StrongerBC Economic Plan, the fund supports advanced manufacturing capabilities in the province through capital investment for new or renovated infrastructure, technology, equipment and processes.

Making connections through trade missions

Trade missions are an opportunity to promote B.C. as a global innovation leader and connect with potential investors and partners. In June 2023, Minister Brenda Bailey attended the BIO International Convention in Boston, along with representatives of more than 45 B.C. companies. Other trade missions to JP Morgan week in San Francisco, Taiwan and Singapore have helped build B.C.’s brand and reputation with global companies and investors.

Strategic support for entrepreneurs

In July 2023, the Province released the B.C. Intellectual Property Strategy to help B.C. entrepreneurs and businesses understand how to use and protect their intellectual property. Through training opportunities, a resource hub and other initiatives, innovators are provided supports to help navigate complex financial and legal issues to protect their ideas and compete here at home and internationally.

Other initiatives are supporting our innovation ecosystem. Through the Trade Diversification Strategy, the B.C. Government is making it easier for businesses to access opportunities in new markets. Clean and Competitive: A Blueprint for B.C.’s Industrial Future lays out the Province’s work to drive new investment, create new jobs and seize new opportunities in growing industries.
Our Progress
Pillar 3: Increasing biomanufacturing capacity and attracting anchor companies

Large anchor companies are the backbone of a strong sector, providing a significant competitive advantage in fostering collaboration. They connect us to global supply chains, allow for talent mobility, help build thriving ecosystems more likely to generate investment, and are important research partners with post-secondary institutions. Biomanufacturing businesses play a critical role within this hub of activity, further strengthening links to internal and external markets.

**To grow and attract anchor companies and increase B.C.’s biomanufacturing capacity, the Province has committed to:**

- Streamlining access to light industrial zoned land and buildings for biomanufacturing activity
- Establishing mechanisms to attract investment and co-invest in strategic projects that will expand clean biomanufacturing operations

**Supporting the growth of a B.C. success story**

AbCellera is a B.C. headquartered company focused on bringing innovative medicines to patients. AbCellera works at the leading edge of antibody drug discovery and development, having expanded from just six employees in a lab at UBC in 2012 to more than 600 employees worldwide. In May 2023, the Province announced a $75-million contribution to AbCellera’s growth in Vancouver to build new capabilities and infrastructure to create innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. This co-investment – along with a contribution of $225 million from the federal government – will create hundreds of new highly skilled jobs.
Advancing the power of nuclear medicine

TRIUMF is Canada’s particle accelerator centre and a driving force in the province’s innovation ecosystem. Its cyclotrons (including the world’s largest conventional cyclotron) produce isotopes used to diagnose and treat disease. A new building on the TRIUMF campus, the Institute for Advanced Medical Isotopes, will support cancer research, produce radio-therapeutics, and deliver on the priorities of B.C.’s 10-year cancer action plan. In January 2024, the Province announced $32 million in funding to expand TRIUMF’s laboratory capacity for industry and provide production space for BC Cancer. When operational in 2026, the new facilities will advance the province’s leadership in nuclear medicine, including targeted therapies that can deliver radiation directly to cancer cells.

Advancing regenerative medicine

Vancouver-based Aspect Biosystems uses 3D bioprinting technology to develop new tissue therapeutics. The Province is investing $23.75 million to support the company’s expansion and build a full-stack biomanufacturing facility in B.C. This investment follows the company’s $3.5-billion deal with global powerhouse Novo Nordisk to develop 3D bioprinted tissue therapeutics to offer a new class of treatments for diabetes and obesity.

“This is exactly what we want to see. Canadian governments supporting domestic companies to grow and create wealth for our economy. This is a prosperity strategy that leads to higher GDP per capita!”

Benjamin Bergen, president of the Council of Canadian Innovators
Our Progress
Pillar 4: Expanding our clinical trials capacity

Building our clinical trials capacity is an essential element in growing the life sciences and biomanufacturing sector. Enabling B.C. companies to test their early-stage products here at home will accelerate access to new life-changing treatments for the people of British Columbia and reduce the gap between innovative research and leading-edge health care.

By expanding the Province’s clinical trials capacity, B.C. will:

1. Maximize the health, educational and economic benefits of clinical trials for British Columbians

Investing in B.C.’s first non-cancer Phase 1 clinical trials unit

Early-stage clinical trials assess whether therapeutics are safe and effective. However, since B.C. does not have clinical trial capacity for non-cancer Phase 1 trials, companies must currently test their discoveries outside of our borders. In October 2023, the Province funded $4.2 million to create a Phase 1 clinical trials unit at Mount Saint Joseph Hospital in Vancouver. The six-bed unit will open in late 2024 and will be the first non-cancer Phase 1 clinical trials unit in B.C. This significant milestone supports local companies to grow their intellectual property here at home and will enable B.C. residents to access life-changing treatments.

Funding a research chair focusing on clinical trials

B.C. is investing $2.4 million to support the establishment of an endowed research chair at UBC to accelerate the design and implementation of clinical trials for next-generation therapeutics. The chair holder will work with the new clinical trials unit at Mount Saint Joseph Hospital and lead a research and education program in clinical pharmacology.
Collaborating to enhance clinical trials in B.C.

Transformative change starts with a shared vision. In 2023, Michael Smith Health Research BC – the province’s health research agency – consulted with over 170 stakeholders province-wide to develop a shared vision for clinical trials in the province. The new vision creates the space for a collaborative and multi-partner approach that aligns efforts across research sites, institutes and health authorities.

Streamlining the approval process for health research

While there are established review processes for health research studies, these often vary from site to site and across health authorities. The Ministry of Health, in partnership with B.C.’s health authorities, is undertaking a project to streamline approval processes for research projects occurring across more than one health authority. The goal of this project is to ensure safe and high-quality research is approved in a timely fashion.
Decades of targeted investments have propelled B.C. to a leading position in life science breakthroughs, from mRNA technology to advances in antibodies and genomics. By continuing to support fundamental and applied research through investments in infrastructure at post-secondary institutions, the Province is setting the stage for a sustainable life sciences sector for decades to come.

**To leverage and commercialize research capacity, B.C. has committed to:**

- Supporting academic research for new therapeutics and biomanufacturing
- Encouraging research translation and commercialization

**Investing in research infrastructure**

The B.C. Knowledge Development Fund makes ongoing strategic investments in labs and equipment at the post-secondary institutions where B.C. researchers are carrying out groundbreaking research. Since 2023, these have included $38 million for 39 projects connected to the life sciences, including a digital health technology and data-sharing hub at the University of Victoria to address non-communicable chronic disease; a metabolic analysis platform at UBC to develop novel obesity and diabetes therapeutics; and a molecular microbiology lab at Simon Fraser University (SFU) exploring new therapies to prevent antibiotic resistance.

**Increasing funding for life-saving research**

Through the StrongerBC Economic Plan, the Province provided a record $195 million in grant funding to Michael Smith Health Research BC and Genome BC. That funding has supported scholars to work on topics such as gut diseases, multiple sclerosis and spinal cord injury. It has also supported important genomic research, such as identifying new therapies to treat children with pediatric acute myeloid leukemia and predicting allergies in children.

In June 2023, the Province announced $20 million in funding over two years to Canada’s Michael Smith Genome Sciences Centre (GSC). The groundbreaking research conducted at the GSC has directly contributed to B.C.’s reputation as a global genomics leader. This investment will strengthen GSC as a provincial hub, and the B.C. Government, BC Cancer, Genome BC, UBC, SFU, the BC Cancer Foundation and other national partners will work together to develop and implement GSC’s updated vision.
Supporting a national research hub

In March 2023, the federal government announced that B.C. will be home to Canada’s Immuno-Engineering and Biomanufacturing Hub. Led by UBC, the hub is a coalition of more than 50 partners from the academic, public, not-for-profit and private sectors that are advancing next-generation immune-based therapeutics. It represents a seamless approach to product development, from research and manufacturing to clinical trials and commercialization.

“This new Life Sciences and Biomanufacturing Strategy will supercharge our already world-class life sciences sector and position us as a global leader in research and innovation, delivering new technologies and treatments that benefit B.C., Canada and the world.”

Suzanne Gill, president and CEO of Genome BC
Rendition of the new St. Paul’s Hospital and Clinical Support and Research Centre on the Jim Pattison Medical Campus. Credit: Providence Health Care
New innovation building at St. Paul’s Hospital: Bridging the gap between research and patient care

It will be like nothing else in the country when it opens in late 2028. The Clinical Support and Research Centre on the Jim Pattison Medical Campus, connected with a sky-bridge to the new St. Paul’s Hospital, will create the spaces and provide the resources for Providence Health Care’s world-class researchers alongside leaders in life sciences, technology and medicine to advance discoveries from the lab to the hospital and beyond.

As part of Western Canada’s first integrated health campus and first research facility with the capacity to conduct all phases of clinical trials, the Clinical Support and Research Centre brings together global research and local health care delivery, demonstrating how collaborative partnerships can lead to life-changing innovations.

Researchers, physicians and clinician-scientists, the life sciences industry and academia will benefit from access to state-of-the-art labs and equipment. This will include cutting-edge wet and dry labs; the technology infrastructure needed for advanced data analytics, AI, machine learning, 3D bioprinting and augmented reality; and a robust network of tissue specimen biobanks poised to be Canada’s largest.

The Province is contributing $331.7 million towards this transformative project, representing just over half of the total capital costs for the building.

“A nexus of discovery and clinical sciences, the Clinical Support and Research Centre will expedite life-changing findings, speed up technology transfer, incubate new startup ventures and provide substantial training opportunities that will push the boundaries of science, innovation and care. In doing so, it will not only elevate the landscape of scientific achievement, but also drive economic growth, not just in B.C., but across Canada.”

Dr. Darryl Knight, president, Providence Research; PHC vice-president, Research and Academic Affairs; and associate dean, Research, Faculty of Medicine, UBC
A healthy future

An incredible amount has been achieved in the 12 months since the release of the Life Sciences and Biomanufacturing Strategy. The accomplishments of the past year show what’s possible when we unite around a shared vision.

As a Province, we’re making significant investments in the people, infrastructure and projects that will help us compete globally and improve health outcomes locally. We will continue to advocate for the life sciences sector nationally and internationally to position B.C. as a global hub for life sciences and biopharmaceutical and medical manufacturing.

We’ll also continue to consult with our partners in B.C.’s exceptional post-secondary institutions. They are training the next generation of leaders in the sector while also conducting essential research that is leading to breakthrough discoveries. And we’ll continue to work with our partners in the private sector to create the conditions where they can grow and thrive here in B.C., attracting the investments they need to compete and gain market share.

This collaborative approach will generate tangible results. It will grow our innovation economy, generate high-paying jobs, improve our ability to respond to future pandemics or public health emergencies, and enable British Columbians to access life-changing therapeutics that are not yet commercially available.

Above all, this strategy is an investment in health – in our innovation economy, in our talented people who want to use their skills to improve quality of life, and in the people of British Columbia.

A scientist performs hand-held magnetic cell isolation in the lab at STEMCELL Technologies. Credit: STEMCELL Technologies
1. StarFish Medical. A medical optical engineer adjusts the alignment of a proof-of-concept optical probe system for a medical device.


3. Diamond Schmitt Architects. Rendering of the Clinical Support and Research Centre, opening in 2028, on the new St. Paul’s Hospital campus in Vancouver.

4. Axolotl Biosciences. Miniature human liver model being printed using the CELLINK BIO X.

5. STEMCELL Technologies. A quality control technician inspects bottles of cell culture media supplement.

6. StarFish Medical. An electrical engineer troubleshoots and repairs the electrical controller of a medical device.


8. STEMCELL Technologies. A scientist prepares a whole blood sample for magnetic cell isolation.


A Technician prepares a sub-assembly for packaging. Credit: StarFish Medical
A radiopharmaceutical production chemist inspects radioisotope development apparatus within a shielded hotcell. Credit: TRIUMF
Questions can be sent to the following email: BCLifeSciencesStrategy@gov.bc.ca

For more information about B.C.’s Life Sciences and Biomanufacturing Strategy, please visit the Ministry of Jobs, Economic Development and Innovation’s sector webpage:

gov.bc.ca/gov/content/governments/technology-innovation/life-sciences-biomanufacturing